Bruker (NASDAQ:BRKR) Price Target Lowered to $60.00 at The Goldman Sachs Group

Bruker (NASDAQ:BRKR) had its price target lowered by The Goldman Sachs Group from $72.00 to $60.00 in a research note released on Tuesday, Benzinga reports. The Goldman Sachs Group currently has a sell rating on the medical research company’s stock.

BRKR has been the topic of a number of other research reports. Stifel Nicolaus dropped their price objective on Bruker from $81.00 to $77.00 and set a hold rating on the stock in a report on Monday, May 20th. StockNews.com downgraded Bruker from a buy rating to a hold rating in a report on Tuesday, May 21st. Jefferies Financial Group assumed coverage on Bruker in a report on Monday, June 3rd. They issued a buy rating and a $85.00 price objective on the stock. Finally, Bank of America dropped their price target on Bruker from $95.00 to $90.00 and set a buy rating on the stock in a research note on Monday, May 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $81.78.

Bruker Price Performance

BRKR stock opened at $63.72 on Tuesday. Bruker has a 1 year low of $53.79 and a 1 year high of $94.86. The firm has a market capitalization of $9.26 billion, a P/E ratio of 23.17, a P/E/G ratio of 2.10 and a beta of 1.20. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.81 and a quick ratio of 0.91. The business’s 50-day moving average is $68.43 and its two-hundred day moving average is $76.67.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The business had revenue of $721.70 million for the quarter, compared to the consensus estimate of $729.88 million. During the same quarter in the prior year, the business posted $0.64 EPS. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Analysts anticipate that Bruker will post 2.66 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 17th. Shareholders of record on Monday, June 3rd were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 3rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.31%. Bruker’s payout ratio is 7.27%.

Institutional Trading of Bruker

A number of hedge funds have recently added to or reduced their stakes in the stock. Linden Thomas Advisory Services LLC lifted its position in Bruker by 16.8% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 19,357 shares of the medical research company’s stock worth $1,235,000 after acquiring an additional 2,784 shares during the period. CWM LLC lifted its position in Bruker by 165.4% during the 2nd quarter. CWM LLC now owns 4,777 shares of the medical research company’s stock worth $305,000 after acquiring an additional 2,977 shares during the period. EverSource Wealth Advisors LLC lifted its position in Bruker by 40.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company’s stock worth $81,000 after acquiring an additional 248 shares during the period. DekaBank Deutsche Girozentrale lifted its position in Bruker by 0.6% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 307,040 shares of the medical research company’s stock worth $28,689,000 after acquiring an additional 1,844 shares during the period. Finally, Cetera Advisors LLC acquired a new stake in Bruker during the 1st quarter worth approximately $693,000. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.